Posted by Michael Wonder on 13 Jan 2018
FDA grants fast track designation to Concert Pharmaceuticals' CTP-543 for the treatment of alopecia areata
12 January 2018 - CTP-543 is a novel JAK inhibitor in Phase 2 for alopecia areata as potential first-in-class treatment.
Concert Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.
Concert is conducting a multi-center, double-blind, randomised, placebo-controlled Phase 2a trial to evaluate the safety and efficacy of CTP-543 in adults with moderate-to-severe alopecia areata.
